BACKGROUND: This study aimed to investigate the impact of atorvastatin (Ato) combined with ezetimibe (Eze) for the treatment of carotid atherosclerosis in patients with coronary heart disease (CHD). METHODS: One hundred and forty-eight CHD patients with carotid atherosclerosis were divided into the control (Ato alone) and combination (Ato and Eze) groups. The treatment course was 12 months; patient blood lipids, carotid intima-media thickness (CIMT), and carotid plaque area were measured before and after treatment. RESULTS: Twelve months after treatment, there was a decrease in the CIMT, and the horizontal and vertical axes of the carotid plaque areas in both groups, compared to pretreatment values. The serum low-density lipoprotein cholesterol (LDL-C) levels were significantly decreased (p < 0.05). There were statistically significant differences (p < 0.05) in the LDL-C (2.12 ± 0.58 mmol/L vs. 2.63 ± 0.56 mmol/L) and CIMT (1.06 ± 0.12 mm vs. 1.13 ± 0.11 mm) levels between the combination and the control groups after treatment. Compared to the control group, the horizontal (0.18 ± 0.06 cm2 vs. 0.19 ± 0.05 cm2) and vertical carotid arterial plaque areas (0.40 ± 0.15 cm2 vs. 0.41 ± 0.17 cm2) of the combination group were reduced after treatment. However, the difference was not statistically significant (p > 0.05). CONCLUSIONS: The combination of Ato and Eze further reduces LDL-C levels and CIMT, and affect the progression of carotid atherosclerosis in CHD patients with hypercholesterolemia.
BACKGROUND: This study aimed to investigate the impact of atorvastatin (Ato) combined with ezetimibe (Eze) for the treatment of carotid atherosclerosis in patients with coronary heart disease (CHD). METHODS: One hundred and forty-eight CHD patients with carotid atherosclerosis were divided into the control (Ato alone) and combination (Ato and Eze) groups. The treatment course was 12 months; patient blood lipids, carotid intima-media thickness (CIMT), and carotid plaque area were measured before and after treatment. RESULTS: Twelve months after treatment, there was a decrease in the CIMT, and the horizontal and vertical axes of the carotid plaque areas in both groups, compared to pretreatment values. The serum low-density lipoprotein cholesterol (LDL-C) levels were significantly decreased (p < 0.05). There were statistically significant differences (p < 0.05) in the LDL-C (2.12 ± 0.58 mmol/L vs. 2.63 ± 0.56 mmol/L) and CIMT (1.06 ± 0.12 mm vs. 1.13 ± 0.11 mm) levels between the combination and the control groups after treatment. Compared to the control group, the horizontal (0.18 ± 0.06 cm2 vs. 0.19 ± 0.05 cm2) and vertical carotid arterial plaque areas (0.40 ± 0.15 cm2 vs. 0.41 ± 0.17 cm2) of the combination group were reduced after treatment. However, the difference was not statistically significant (p > 0.05). CONCLUSIONS: The combination of Ato and Eze further reduces LDL-C levels and CIMT, and affect the progression of carotid atherosclerosis in CHD patients with hypercholesterolemia.
Authors: Hong H Keo; Iris Baumgartner; Alan T Hirsch; Sue Duval; Ph Gabriel Steg; Blandine Pasquet; Deepak L Bhatt; Joachim Roether Journal: Vasc Med Date: 2011-09-09 Impact factor: 3.239
Authors: T E Craven; J E Ryu; M A Espeland; F R Kahl; W M McKinney; J F Toole; M R McMahan; C J Thompson; G Heiss; J R Crouse Journal: Circulation Date: 1990-10 Impact factor: 29.690
Authors: Christopher P Cannon; Robert P Giugliano; Michael A Blazing; Robert A Harrington; John L Peterson; Christine McCrary Sisk; John Strony; Thomas A Musliner; Carolyn H McCabe; Enrico Veltri; Eugene Braunwald; Robert M Califf Journal: Am Heart J Date: 2008-09-02 Impact factor: 4.749
Authors: JoAnne M Foody; Peter P Toth; Joanne E Tomassini; Shiva Sajjan; Dena R Ramey; David Neff; Andrew M Tershakovec; Henry Hu; Kaan Tunceli Journal: Vasc Health Risk Manag Date: 2013-11-15